Pharmaceutical Distribution in the US: Current and Future Perspectives
Author: Dr Faiz Kermani
Publication date: July 2009
Number of pages: 83
- Electronic copy (single user): £1,495
- Printed copy (single user): £1,550
Download full report details (including table of contents)
Download order form
In the US, the pharmaceutical supply chain involves the daily delivery of approximately 13 million prescription products to pharmacies, hospitals, clinics and other healthcare provider locations.
Pharmaceutical Distribution in the US - Current and Future Perspectives delivers a comprehensive and expert overview of the distribution of medicines in the United States. This 40,000 word report will provide the reader with accurate insight into this complex and rapidly changing sector.
Some key findings from this report include:
- In 2008 the US pharmaceutical wholesale market was worth $275bn.
- McKesson, AmerisourceBergen and Cardinal Health Inc, known as the ‘Big Three', account for between 90-95% of revenue within the US pharmaceutical wholesale sector.
- The ‘Big Three' have been responsible for over 100 buyouts since 1980, at least 57 of which have occurred over the past decade.
- It is estimated that US chain drug stores currently account for 41% of all prescription sales, with the dominant players being Walgreens and CVS Caremark.
- A change from wholesale to direct distribution in the US is unlikely. A US wide direct distribution model would cost the pharmaceutical industry $47.9bn to operate. This would be 15.5% increase on current distribution costs.
Use this report to:
- Understand the environment for medicines distribution in the US.
- Identify where the sector might change in the next few years. Analyse threats and opportunities.
- Spot potential areas of pharmaceutical distribution market growth and opportunities for delivering successful sales growth.